Interleukin-2 (IL-2) as a consolidative treatment after autologous bone marrow transplantation for hematologic malignancies.

被引：0
|
作者：
Massumoto, C [1 ]
Ostronoff, M [1 ]
Macedo, MCMA [1 ]
ZAmbon, E [1 ]
Medeiros, RSS [1 ]
DorlhiacLlacer, PE [1 ]
Chamone, DAF [1 ]
Dulley, F [1 ]
机构：
[1] UNIV SAO PAULO,HEMOCTR SAO PAULO,FDN PRO SANGUE,BR-05508 SAO PAULO,BRAZIL
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3817 / 3817
页数：1
相关论文
共 50 条
  • [31] Immunotherapy with interleukin-2 after autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML).
    Massumoto, CM
    Macedo, MCA
    Saboya, R
    Silva, R
    Loterio, H
    Dzik, C
    Pallotta, R
    Chamone, DAF
    Dulley, F
    BLOOD, 1997, 90 (10) : 4566 - 4566
  • [32] Immunologic effects of interleukin-12 therapy after autologous stem cell transplantation for hematologic malignancies.
    Robertson, MJ
    Pelloso, D
    Timmons, L
    Williams, BT
    BLOOD, 2001, 98 (11) : 691A - 691A
  • [33] Second cancers after non-autologous bone marrow transplantation for hematologic malignancies
    Kulkarni, S
    Powles, R
    Singhal, S
    Mehta, J
    Treleaven, J
    Horton, C
    Meller, S
    Pinkerton, CR
    Atra, A
    Tait, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 211 - 211
  • [34] INTERLEUKIN-2 WITH OR WITHOUT LYMPHOKINE-ACTIVATED KILLER-CELLS AS CONSOLIDATIVE IMMUNOTHERAPY AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA
    BENYUNES, MC
    MASSUMOTO, C
    YORK, A
    HIGUCHI, CM
    BUCKNER, CD
    THOMPSON, JA
    PETERSEN, FB
    FEFER, A
    BONE MARROW TRANSPLANTATION, 1993, 12 (02) : 159 - 163
  • [35] INTERLEUKIN-2 (IL-2) RESTORATION OF DEFECTIVE INVITRO LYMPHOCYTE-PROLIFERATION FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
    LENARSKY, C
    WEINBERG, K
    PETERSEN, J
    PARKMAN, R
    PEDIATRIC RESEARCH, 1987, 21 (04) : A313 - A313
  • [36] INTERLEUKIN-2 (IL-2) IMMUNOTHERAPY
    MACEY, MG
    JOHNSTON, DH
    MEDICAL LABORATORY SCIENCES, 1990, 47 (03): : 220 - 225
  • [37] PHASE-I TRIAL OF INTERLEUKIN-2 (IL-2) AFTER UNMODIFIED HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION (BMT)
    BENYUNES, MC
    SANDERS, JE
    BEACH, C
    THOMPSON, JA
    LINDGREN, C
    APPELBAUM, FR
    FEFER, A
    BLOOD, 1994, 84 (10) : A332 - A332
  • [38] THE GRAFT-VS-LEUKEMIA REACTION (GVLR) AND INTERLEUKIN-2 (IL-2) AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) - PRECLINICAL STUDIES
    KLOOSTERMAN, TC
    MARTENS, ACM
    VANBEKKUM, DW
    HAGENBEEK, A
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 721 - 721
  • [39] INTERLEUKIN-3 FOR GRAFT FAILURE FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
    CRUMP, M
    COUTURE, F
    KOVACS, M
    ZOLLINGER, L
    MCCRAE, J
    KEATING, A
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 772 - 772
  • [40] A phase II study of daily subcutaneous (SQ) low dose interleukin-2 (IL-2) in HIV-associated malignancies.
    Bernstein, ZP
    Barresi, G
    Gould, M
    Poiesz, B
    Caligiuri, MA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (04): : 96 - 96
12345